# Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects

> **NCT02508896** · PHASE1 · COMPLETED · sponsor: **Affiris AG** · enrollment: 72 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **BIOLOGICAL:** AFFITOPE® AT04A+adjuvant
- **BIOLOGICAL:** AFFITOPE® AT06A+adjuvant
- **BIOLOGICAL:** Adjuvant without active component

## Key facts

- **NCT ID:** NCT02508896
- **Lead sponsor:** Affiris AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2016-05
- **Final completion:** 2017-08-31
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2017-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02508896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02508896, "Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02508896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*